explore -WSS

explore

author：hotspot 2025-10-02 01:52:52 - browse：25517

Telehealth menopause treatment options displayed on cellphones emerging from a crack in the ground. -- health tech coverage from STAT — Molly Ferguson for STAT

At the turn of the century, nearly 18 million women in the United States were battling hot flashes, night sweats, and other symptoms of menopause with hormones. But in 2002, the therapy went into a free-fall when a landmark trial suggested treating menopause with estrogen and progesterone increased the risk of breast cancer and cardiovascular disease. The study was shut down early — and a year later, prescriptions had plummeted to nearly half what they had been in 2001.

More than two decades later, menopause experts have come to think about the results of the trial very differently. Newer research points to more benefits than risks for many healthy women under 60 treating menopause symptoms with hormone therapy. But many women who are good fits still aren’t getting treatment. “The pendulum has been slowly — too slowly — swinging back,” said OB-GYN Mike Green, chief medical officer of menopause telehealth company Winona.

Winona is part of a new generation of virtual-first health care companies aiming to give that pendulum a push. In the last five years, more than a dozen telehealth companies have started up to serve women in and approaching menopause, including with hormone therapy.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Merck, Daiichi strike cancer drug pact worth up to $22 billion

WSS

3 medical device trends to watch in 2024

Readout LOUD podcast: Live from the 2023 STAT Summit

Ahead of JPM, here's who's profiting most in health care

Morgan Health, with ambitious aims, wants you to know it’s still here

FDA clears Verve to begin U.S. study of gene

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

explore

explore

focus

How one medical school became remarkably diverse

Goldman Sachs launches $650M fund for life science investments

Medicare proposal to cover medical devices draws a mixed reaction

Roche acquires Telavant from Roivant, adding experimental IBD treatment

Moonlake's readout produced a cash windfall. Risks remain

The problems with dementia villages

Walensky prepares to leave CDC — and Congress — behind

Ahead of JPM, here's who's profiting most in health care

Malaria cases in Florida and Texas: Here’s what you need to know

Readout LOUD podcast: Live from the 2023 STAT Summit

hotspot

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

JPM: CVS says Medicare Advantage patients are impacting profits

The biotech scorecard for Q1: 17 stock

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

GSK Flovent asthma inhalers replaced by authorized generics

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

hotspot

entertainment

hotspot

Wikipedia